Valbenazine | NBI-98854 | VMAT2 Inhibitor | AmBeed-信号通路专用抑制剂

首页 / 抑制剂/激动剂 / 膜转运蛋白 / MAT / Valbenazine

Valbenazine {[allProObj[0].p_purity_real_show]}

货号：A348606 同义名： NBI-98854

Valbenazine is a prodrug of the(+)-α isomer of tetrabenazine for tardive syndrome therapy, and inhibits VMAT2 function.

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Valbenazine 化学结构
CAS号：1025504-45-3

Valbenazine 3D分子结构
CAS号：1025504-45-3

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Valbenazine 纯度/质量文件产品仅供科研

货号：A348606 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • JACS Au, 2024. Ambeed. [ A148168 ]; • JMC, 2024. Ambeed. [ A187643 ]; • JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]; • Biomacromolecules, 2024. Ambeed. [ A110759 ]; • Biomacromolecules, 2024. Ambeed. [ A203543 ]; 更多 >

Valbenazine 生物活性

描述	Valbenazine is a potent inhibitor of the vesicular monoamine transporter 2 (VMAT2), with a Ki range of 110-190 nM^[1].
体内研究	When administered orally at a dosage of 10 mg/kg, Valbenazine causes ptosis, which is primarily an adrenergic response, and increases plasma prolactin levels, mainly a dopaminergic response in rats^[1].
体外研究	Valbenazine demonstrates high VMAT2 binding affinity both in rat striatum and human platelets, showing Kis of 110 and 150 nM, respectively^[1].

Valbenazine 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02679079	Tourette Syndrome	Phase 2	Completed	-	-
NCT02879578	Tourette Syndrome	Phase 2	Completed	-	United States, Arizona ... 展开 >> Sun City, Arizona, United States United States, California San Diego, California, United States United States, Florida Loxahatchee Groves, Florida, United States Saint Petersburg, Florida, United States Tampa, Florida, United States United States, Illinois Naperville, Illinois, United States United States, Nebraska Lincoln, Nebraska, United States United States, New Jersey Summit, New Jersey, United States United States, New York New York, New York, United States United States, Pennsylvania Norristown, Pennsylvania, United States United States, Tennessee Nashville, Tennessee, United States United States, Texas Fort Worth, Texas, United States United States, Washington Spokane, Washington, United States 收起 <<
NCT02581865	Tourette Syndrome	Phase 2	Completed	-	-

Valbenazine 参考文献

[1]Dimitri E Grigoriadis, et al. Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites. J Pharmacol Exp Ther. 2017 Jun;361(3):454-461.

Valbenazine 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.39mL

0.48mL

0.24mL

11.95mL

2.39mL

1.19mL

23.89mL

4.78mL

2.39mL

Valbenazine 技术信息

CAS号	1025504-45-3
分子式	C₂₄H₃₈N₂O₄
分子量	418.57

别名	NBI-98854
运输	蓝冰

存储条件

粉末 Keep in dark place,Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 50 mg/mL(119.45 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02679079	Tourette Syndrome	Phase 2	Completed	-	-
NCT02879578	Tourette Syndrome	Phase 2	Completed	-	United States, Arizona ... 展开 >> Sun City, Arizona, United States United States, California San Diego, California, United States United States, Florida Loxahatchee Groves, Florida, United States Saint Petersburg, Florida, United States Tampa, Florida, United States United States, Illinois Naperville, Illinois, United States United States, Nebraska Lincoln, Nebraska, United States United States, New Jersey Summit, New Jersey, United States United States, New York New York, New York, United States United States, Pennsylvania Norristown, Pennsylvania, United States United States, Tennessee Nashville, Tennessee, United States United States, Texas Fort Worth, Texas, United States United States, Washington Spokane, Washington, United States 收起 <<
NCT02581865	Tourette Syndrome	Phase 2	Completed	-	-
NCT02256475	Tourette Syndrome	Phase 1	Completed	-	United States, California ... 展开 >> San Diego, California, United States United States, Florida Kissimmee, Florida, United States St. Petersburg, Florida, United States United States, Illinois Naperville, Illinois, United States United States, Missouri St. Louis, Missouri, United States United States, Nebraska Lincoln, Nebraska, United States United States, New York New York, New York, United States Rochester, New York, United States United States, Virginia Petersburg, Virginia, United States United States, Washington Kirkland, Washington, United States 收起 <<
NCT01393600	Tardive Dyskinesia	Phase 2	Completed	-	United States, Arkansas ... 展开 >> Woodland International Research Group, Inc Little Rock, Arkansas, United States, 72211 United States, California Synergy Clinical Research National City, California, United States, 91950 UCSD Outpatient Psychiatry San Diego, California, United States, 92103 PCSD - Feighner Research San Diego, California, United States, 92108 United States, Florida San Marcus Research Clinic, Inc. Miami, Florida, United States, 33015 Medical Research Marseilles Miami, Florida, United States, 33155 Scientific Clinical Research, Inc. North Miami, Florida, United States, 33161 United States, Georgia Atlanta Center for Medical Research Atlanta, Georgia, United States, 30308 United States, Missouri St. Louis Clinical Trials Saint Louis, Missouri, United States, 63118 United States, Texas Clinical Trials of Texas, Inc. San Antonio, Texas, United States, 78229 United States, West Virginia CAMC Clinical Trials Center Charleston, West Virginia, United States, 25304 收起 <<
NCT01733121	Tardive Dyskinesia	Phase 2	Completed	-	United States, California ... 展开 >> Costa Mesa, California, United States, 92626 Fountain Valley, California, United States, 92708 Oceanside, California, United States, 92056 United States, Colorado Englewood, Colorado, United States, 80113 United States, Florida Boca Raton, Florida, United States, 33486 Hialeah, Florida, United States, 33012 Miami, Florida, United States, 33125 United States, Illinois Chicago, Illinois, United States, 60640 United States, Maryland Baltimore, Maryland, United States, 21287 United States, Michigan Farmington Hills, Michigan, United States, 48334 United States, Ohio Beachwood, Ohio, United States, 44122 Middleburg Heights, Ohio, United States, 44130 United States, Pennsylvania Conshohocken, Pennsylvania, United States, 19428 Phoenixville, Pennsylvania, United States, 19460 United States, Texas Bedford, Texas, United States, 76021 DeSoto, Texas, United States, 75115 Houston, Texas, United States, 77008 Houston, Texas, United States, 77030 Irving, Texas, United States, 75062 San Antonio, Texas, United States, 78229 United States, Washington Richland, Washington, United States, 99352 Puerto Rico Caguas, Puerto Rico, 00725 收起 <<
NCT01267188	Tardive Dyskinesia	Phase 2	Completed	-	Canada, Ontario ... 展开 >> Toronto, Ontario, Canada, M5T 1R8 收起 <<
NCT01688037	Tardive Dyskinesia	Phase 2	Completed	-	-
NCT01733121	-		Completed	-	-
NCT01393600	-		Completed	-	-
NCT01688037	-		Completed	-	-
NCT02274558	Tardive Dyskinesia	Phase 3	Completed	-	-
NCT02405091	Tardive Dyskinesia	Phase 3	Completed	-	-
NCT02274558	-		Completed	-	-
NCT01910480	Effect of Ketoconazole on the ... 展开 >>PK of NBI-98854 in Healthy Subjects 收起 <<	Phase 1	Completed	-	United States, Arizona ... 展开 >> Celerion Tempe, Arizona, United States, 85283 收起 <<
NCT01916993	Safety, Tolerability, and PK o... 展开 >>f NBI-98854 in Hepatically Impaired Subjects 收起 <<	Phase 1	Completed	-	United States, Colorado ... 展开 >> DaVita Clinical Research Lakewood, Colorado, United States, 80228 United States, Florida Orlando Clinical Research Center Orlando, Florida, United States, 32809 United States, Minnesota Davita Clinical Research Minneapolis, Minnesota, United States, 55404 收起 <<
NCT03325010	Tourette Syndrome	Phase 2	Recruiting	December 2018	-
NCT02405091	-		Completed	-	-
NCT03732534	Tourette Syndrome	Phase 2	Enrolling by invitation	August 2020	United States, California ... 展开 >> Neurocrine Clinical Site Anaheim, California, United States, 92805 Neurocrine Clinical Site San Diego, California, United States, 92108 United States, Florida Neurocrine Clinical Site Hialeah, Florida, United States, 33013 United States, Illinois Neurocrine Clinical Site Chicago, Illinois, United States, 60634 Neurocrine Clinical Site Naperville, Illinois, United States, 60563 United States, Nebraska Neurocrine Clinical Site Lincoln, Nebraska, United States, 68526 United States, Texas Neurocrine Clinical Site Houston, Texas, United States, 77058 收起 <<
NCT03444038	Tourette Syndrome	Phase 2	Enrolling by invitation	June 2019	-
NCT03530293	Tourette Syndrome	Phase 2	Recruiting	February 2020	-
NCT03698331	Tardive Dyskinesia (TD)	Phase 4	Recruiting	April 2019	United States, California ... 展开 >> Neurocrine Clinical Site Recruiting Anaheim, California, United States, 92804 Neurocrine Clinical Site Recruiting Glendale, California, United States, 91206 Neurocrine Clinical Site Recruiting Norwalk, California, United States, 90650 Neurocrine Clinical Site Recruiting Oceanside, California, United States, 92054 Neurocrine Clinical Site Recruiting San Bernardino, California, United States, 92108 United States, Florida Neurocrine Clinical Site Recruiting Hialeah, Florida, United States, 33012 Neurocrine Clinical Site Recruiting Hialeah, Florida, United States, 33013 Neurocrine Clinical Site Recruiting Hialeah, Florida, United States, 33018 United States, Hawaii Neurocrine Clinical Site Recruiting Honolulu, Hawaii, United States, 96817 United States, Michigan Neurocrine Clinical Site Recruiting Ann Arbor, Michigan, United States, 48105 United States, Ohio Neurocrine Clinical Site Recruiting Beechwood, Ohio, United States, 44122 United States, Oklahoma Neurocrine Clinical Site Recruiting Oklahoma City, Oklahoma, United States, 73112 United States, Pennsylvania Neurocrine Clinical Site Recruiting Scranton, Pennsylvania, United States, 18503 United States, Texas Neurocrine Clinical Site Recruiting DeSoto, Texas, United States, 75115 Neurocrine Clinical Site Recruiting Irving, Texas, United States, 75062 Puerto Rico Neurocrine Clinical Site Recruiting San Juan, Puerto Rico, 00926 收起 <<
NCT02736955	Tardive Dyskinesia	Phase 3	Unknown	-	-

Valbenazine {[allProObj[0].p_purity_real_show]}

Valbenazine 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Valbenazine 质控信息

Valbenazine 生物活性

Valbenazine 临床研究

Valbenazine 参考文献

Valbenazine 实验方案

Valbenazine 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Valbenazine {[allProObj[0].p_purity_real_show]}

Valbenazine 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Valbenazine 质控信息

Valbenazine 生物活性

Valbenazine 临床研究

Valbenazine 参考文献

Valbenazine 实验方案

Valbenazine 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Valbenazine 纯度/质量文件产品仅供科研